Genomic Studies of Suicidal Thoughts and Behaviors in Latin American Populations: A Systematic Review.

Biol PsychiatryJan 13, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Brenda Cabrera-Mendoza, Alana Castro Panzenhagen, Guillermo de Anda-Jáuregui et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review synthesized molecular studies of suicidal ideation, suicide attempts, nonsuicidal self-injury, and suicide death among Latin American or Hispanic/Latinx populations. It included 59 studies: 3 family, 50 genetic, 6 transcriptomic, and 3 epigenetic studies, with categories not mutually exclusive. Candidate-gene findings were inconsistent, and meta-analyses found no significant associations for TPH1 (rs1800532), HTR2A rs6313 (T102C), or 5-HTTLPR (rs25531). Newer genome-wide and polygenic-score studies reported ancestry-specific loci, but the evidence base remains fragmented and underpowered.

Key findings

  • The review included 59 studies: 3 family, 50 genetic, 6 transcriptomic, and 3 epigenetic studies; categories were not mutually exclusive.
  • Meta-analyses found no significant associations for TPH1 (rs1800532), HTR2A rs6313 (T102C), or 5-HTTLPR (rs25531).
  • Genome-wide and polygenic-score studies identified ancestry-specific loci, while small samples and limited functional annotation resources constrained follow-up.
  • Transcriptomic and epigenetic studies implicated neurodevelopmental and immune-related processes; collaboration networks showed limited cross-group integration.

Why it matters

The review highlights a substantial evidence gap in genomic research on suicidality among Latin American and Hispanic/Latinx populations. Inconsistent candidate-gene results and limited representation constrain the interpretation and generalisability of findings. More representative sampling, ancestry-aware analyses, and stronger collaboration could improve the evidence base needed to investigate biological pathways and support future prevention research.

What to keep in mind

The review reports that the underlying literature is fragmented and underpowered; small samples and limited functional annotation resources hindered follow-up of genomic findings.

Source

Published in Biol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.